Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
ObjectiveThis study aimed to examine the very long-term effects of globus pallidus interna (GPi) or subthalamic nucleus (STN) deep brain stimulation (DBS) on Parkinson's disease (PD) in a subset of patients enrolled in the CSP468 VA/NINDS prospective randomized trial.MethodsThe primary outcome was the change in off-medication/on-stimulation Unified Parkinson's Disease Rating Scale III score (UPDRS III) from baseline over time between the two targets at 2, 7, and 10 years. Many secondary outcomes were also explored.ResultsA total of 156 patients were enrolled in this substudy, and data were available for 68 GPi/49 STN participants at 7 years and 49 GPi/28 STN participants at 10 years. There was no overall difference in the time trend between the two targets (p p p p = 0.10), respectively, and in the STN cohort at 2, 7, and 10 years it was 34.9% (p p p ConclusionDBS therapy has a significant beneficial effect on overall motor function, dyskinesia, and motor fluctuations over 10 years (regardless of target), though non-motor symptoms progressed. Bradykinesia, axial, and quality-of-life improvement were maintained at 2 years and then declined over time.Clinical trial registrationClinicalTrials.gov, identifier NCT01022073, NCT00056563, NCT01076452.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.